Expression of HER-2 and leptin in gastric cancer and their clinical significance

Chinese Journal of Oncology

Volumn 33, Issue 10, 2011, Pages 764-769

  Geng, Yi Ting ^a   Qiu, Jin Rong ^a   Wang, Rong ^a   Su, Yun Tao ^a   Shu, Yong Qian ^a   Yin, Yong Mei ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Human epidermal growth factor receptor 2; Leptin; Leptin receptor; Prognosis; Stomach neoplasms; Vascular endothelial growth factor

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LEPTIN; LEPTIN RECEPTOR;

ARTICLE; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER STAGING; CONTROLLED STUDY; DISTANT METASTASIS; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PROGNOSIS; PROTEIN EXPRESSION; STOMACH CANCER; STOMACH MUCOSA; TUMOR VOLUME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GASTRECTOMY; HUMANS; LEPTIN; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, LEPTIN; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 81855218137     PISSN: 02533766     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0253-3766.2011.10.009     Document Type: Article

References (13)

1. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol, 2008, 19:1523-1529.
2. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology, 2008, 52:797-805. (Pubitemid 351724903)
3. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 2010, 376:687-697.
4. Lower EE, Glass E, Blau R, et al. HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat, 2009, 113:301-306.
5. Wu JM, Fackler MJ, Halushka MK, et al. Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res, 2008, 14:1938-1946. (Pubitemid 351551102)
6. Ishikawa M, Kitayama J, Nagawa H. Expression pattern of leptin and leptin receptor (OB-R) in human gastric cancer. World J Gastroenterol, 2006, 12:5517-5522. (Pubitemid 44501812)
7. Zhao X, Huang K, Zhu Z, et al. Correlation between expression of leptin and clinicopathological features and prognosis in patients with gastric cancer. J Gastroenterol Hepatol, 2007, 22:1317-1321. (Pubitemid 47222662)
8. Marx AH, Tharun L, Muth J, et al. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol, 2009, 40:769-777.
9. Tanigawa T, Watanabe T, Otani K, et al. Leptin promotes gastric ulcer healing via upregulation of vascular endothelial growth factor. Digestion, 2010, 81:86-95.
10. Schram K, Wong MM, Palanivel R, et al. Increased expression and cell surface localization of MTI-MMP plays a role in stimulation of MMP-2 activity by leptin in neonatal rat cardiac myofibroblasts. J Mol Cell Cardiol, 2008, 44:874-881.
11. Heida NM, Leifheit-Nestler M, Schroeter MR, et al. Leptin enhances the potency of circulating angiogenic cells via arc kinase and integrin αvβ5: implications for angiogenesis in human obesity. Arterioscler Thromb Vasc Biol, 2010, 30:200-206.
12. Huang F, Xiong X, Wang H, et al. Leptin-induced vascular smooth muscle cell proliferation via regulating cell cycle, activating ERK1/2 and NF-kappaB. Acta Biochim Biophys Sin (Shanghai), 2010, 42:325-331.